ABSTRACT
The rising prevalence of nonsuicidal self-injury (NSSI) in pediatric populations along with the recent inclusion of NSSI as a condition for further study in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) have increased the focus on the assessment and treatment of NSSI among youth. Despite the frequent occurrence of NSSI in inpatient psychiatric treatment settings, there are no empirically based assessment protocols to guide clinical staff. This article presents findings from a needs assessment conducted with staff at a state-run child and adolescent inpatient treatment facility. The purpose was to assess the need for formalized NSSI training among staff. A questionnaire was developed to evaluate whether staff had received formal training in NSSI assessment and treatment as well as typical practice responses to patients engaging in NSSI behaviors. The questionnaire also evaluated staff comfort and confidence in their knowledge and skills concerning the assessment and treatment of NSSI among children and adolescents. Respondents were 126 clinical staff, most of whom were nursing staff. Only a minority of staff reported having received formal NSSI training, and a third of respondents indicated that they do not typically assess for NSSI at all. Although a substantial percentage of clinical staff self-reported comfort and confidence with assessing and treating NSSI, fewer than 10% demonstrated accurate skill. Formal training in NSSI is associated with positive outcomes for both patients and staff in general healthcare settings. These findings suggest that similar training for staff on pediatric inpatient psychiatric units will likely foster comfort, confidence, and accuracy, thereby improving outcomes for children and adolescents engaging in NSSI behaviors.
Subject(s)
Self-Injurious Behavior , Staff Development/methods , Suicidal Ideation , Adolescent , Attitude of Health Personnel , Child , Diagnostic and Statistical Manual of Mental Disorders , Female , Hospitals, Psychiatric/standards , Hospitals, Psychiatric/statistics & numerical data , Humans , Inpatients/psychology , Inpatients/statistics & numerical data , Male , Needs Assessment , Psychological Techniques/education , Quality Improvement , Self-Injurious Behavior/diagnosis , Self-Injurious Behavior/prevention & control , Self-Injurious Behavior/psychology , United StatesABSTRACT
OBJECTIVE: The authors describe a stimulus case that led training staff to examine and revise the supervision policy of the adult and child and adolescent psychiatry clinics. To inform the revisions, the authors reviewed the literature and national policies. METHODS: The authors conducted a literature review in PubMed using the following criteria: Supervision, Residents, Training, Direct, and Indirect and a supplemental review in Academic Psychiatry. The authors reviewed institutional and Accreditation Council for Graduate Medical Education resident and fellow supervision policies to develop an outpatient and fellow supervision policy. RESULTS: Research is limited in psychiatry with three experimental articles demonstrating positive impact of direct supervision and several suggesting different techniques for direct supervision. In other areas of medicine, direct supervision is associated with improved educational and patient outcomes. The authors present details of our new supervision policy including triggers for direct supervision. CONCLUSIONS: The term direct supervision is relatively new in psychiatry and medical education. There is little published on the extent of implementation of direct supervision and on its impact on the educational experience of psychiatry trainees and other medical specialties. Direct supervision has been associated with improved educational and patient outcomes in nonpsychiatric fields of medicine. More research is needed on the implementation of, indications for, and effects of direct supervision on trainee education and on patient outcomes.
Subject(s)
Education, Medical, Graduate , Internship and Residency , Psychiatry/education , Accreditation , Adolescent , Adult , Ambulatory Care Facilities , Child , Child Psychiatry/education , Education, Medical, Graduate/methods , Education, Medical, Graduate/organization & administration , Humans , Male , MentorsABSTRACT
OBJECTIVE: Children with Pervasive Developmental Disorders (PDDs) have social interaction deficits, delayed communication, and repetitive behaviors as well as impairments in adaptive functioning. Many children actually show a decline in adaptive skills compared with age mates over time. METHOD: This 24-week, three-site, controlled clinical trial randomized 124 children (4 through 13 years of age) with PDDs and serious behavioral problems to medication alone (MED; n = 49; risperidone 0.5 to 3.5 mg/day; if ineffective, switch to aripiprazole was permitted) or a combination of medication plus parent training (PT) (COMB; n = 75). Parents of children in COMB received an average of 11.4 PT sessions. Standard scores and Age-Equivalent scores on Vineland Adaptive Behavior Scales were the outcome measures of primary interest. RESULTS: Seventeen subjects did not have a post-randomization Vineland assessment. Thus, we used a mixed model with outcome conditioned on the baseline Vineland scores. Both groups showed improvement over the 24-week trial on all Vineland domains. Compared with MED, Vineland Socialization and Adaptive Composite Standard scores showed greater improvement in the COMB group (p = .01 and .05, and effect sizes = 0.35 and 0.22, respectively). On Age Equivalent scores, Socialization and Communication domains showed greater improvement in COMB versus MED (p = .03 and 0.05, and effect sizes = 0.33 and 0.14, respectively). Using logistic regression, children in the COMB group were twice as likely to make at least 6 months' gain (equal to the passage of time) in the Vineland Communication Age Equivalent score compared with MED (p = .02). After controlling for IQ, this difference was no longer significant. CONCLUSION: Reduction of serious maladaptive behavior promotes improvement in adaptive behavior. Medication plus PT shows modest additional benefit over medication alone. Clinical trial registration information-RUPP PI PDD: Drug and Behavioral Therapy for Children With Pervasive Developmental Disorders; http://www.clinicaltrials.gov; NCT00080145.
Subject(s)
Adaptation, Psychological/drug effects , Antipsychotic Agents/therapeutic use , Child Behavior Disorders/therapy , Child Development Disorders, Pervasive/therapy , Education , Risperidone/therapeutic use , Adolescent , Antipsychotic Agents/adverse effects , Asperger Syndrome/diagnosis , Asperger Syndrome/psychology , Asperger Syndrome/therapy , Autistic Disorder/diagnosis , Autistic Disorder/psychology , Autistic Disorder/therapy , Checklist , Child , Child Behavior Disorders/diagnosis , Child Behavior Disorders/psychology , Child Development Disorders, Pervasive/diagnosis , Child Development Disorders, Pervasive/psychology , Child, Preschool , Combined Modality Therapy , Communication , Cooperative Behavior , Dose-Response Relationship, Drug , Female , Humans , Male , Risperidone/adverse effects , SocializationABSTRACT
OBJECTIVE: Many children with pervasive developmental disorders (PDDs) have serious, functionally impairing behavioral problems. We tested whether combined treatment (COMB) with risperidone and parent training (PT) in behavior management is superior to medication alone (MED) in improving severe behavioral problems in children with PDDs. METHOD: This 24-week, three-site, randomized, parallel-groups clinical trial enrolled 124 children, aged 4 through 13 years, with PDDs, accompanied by frequent tantrums, self-injury, and aggression. The children were randomized 3:2 to COMB (n = 75) or MED (n = 49). The participants received risperidone monotherapy from 0.5 to 3.5 mg/day (with switch to aripiprazole if risperidone was ineffective). Parents in the COMB group (n = 75; 60.5%) received a mean of 10.9 PT sessions. The primary measure of compliance was the Home Situations Questionnaire (HSQ) score. RESULTS: Primary: intent-to-treat random effects regression showed that COMB was superior to MED on HSQ (p = .006) [effect size at week 24 (d) = 0.34]. The HSQ score declined from 4.31 (± 1.67) to 1.23 (± 1.36) for COMB compared with 4.16 (± 1.47) to 1.68 (± 1.36) for MED. Secondary: groups did not differ on Clinical Global Impressions-Improvement scores at endpoint; compared with MED, COMB showed significant reductions on Aberrant Behavior Checklist Irritability (d = 0.48; p = .01), Stereotypic Behavior (d = 0.23; p = .04), and Hyperactivity/Noncompliance subscales (d = 0.55; p = .04). Final risperidone mean dose for MED was 2.26 mg/day (0.071 mg/kg), compared with 1.98 mg/day for COMB (0.066 mg/kg) (p = .04). CONCLUSIONS: Medication plus PT resulted in greater reduction of serious maladaptive behavior than MED in children with PDDs, with a lower risperidone dose.
Subject(s)
Antipsychotic Agents/therapeutic use , Child Behavior Disorders/therapy , Child Development Disorders, Pervasive/therapy , Education , Risperidone/therapeutic use , Adolescent , Antipsychotic Agents/adverse effects , Behavior Therapy , Child , Child Behavior Disorders/diagnosis , Child Behavior Disorders/psychology , Child Development Disorders, Pervasive/diagnosis , Child Development Disorders, Pervasive/psychology , Child, Preschool , Combined Modality Therapy , Dose-Response Relationship, Drug , Double-Blind Method , Female , Humans , Male , Personality Assessment/statistics & numerical data , Psychometrics , Risperidone/adverse effectsABSTRACT
Objective To evaluate gastrointestinal (GI) problems in a large, well-characterized sample of children with pervasive developmental disorders (PDDs). Methods One hundred seventy two children entering one of two trials conducted by the Research Units on Pediatric Psychopharmacology (RUPP) Autism Network were assessed comprehensively prior to starting treatment and classified with regard to GI symptoms. Results Thirty nine (22.7%) were positive for GI problems, primarily constipation and diarrhea. Those with GI problems were no different from subjects without GI problems in demographic characteristics, measures of adaptive functioning, or autism symptom severity. Compared to children without GI problems, those with GI problems showed greater symptom severity on measures of irritability, anxiety, and social withdrawal. Those with GI problems were also less likely to respond to treatment.
Subject(s)
Anxiety/psychology , Autistic Disorder/physiopathology , Autistic Disorder/psychology , Constipation/physiopathology , Diarrhea/physiopathology , Social Behavior Disorders/psychology , Adaptation, Psychological , Adolescent , Autistic Disorder/diagnosis , Child , Child, Preschool , Female , Humans , Male , Severity of Illness IndexABSTRACT
Autistic disorder and the group of related conditions defined as pervasive developmental disorders are chronic neurodevelopmental disorders starting in early childhood and affecting a significant number of children and families. Although the causes and much of the pathophysiology of the disorder remain unknown, in recent years a number of available medication treatments have been identified as holding promise in alleviating some of the most disabling maladaptive behaviors, associated with pervasive developmental disorders. However these treatments do not address the core symptoms of the disease and oftentimes their side effects outweigh their benefits. Therefore there is substantial need for new medications that are safer and more effective in addressing the behavior symptoms of autism. The aim of this review is to highlight the available current pharmacotherapies and those emerging treatments with potential to enhance the treatment options of patients with pervasive developmental disorders.
Subject(s)
Antidepressive Agents/therapeutic use , Antipsychotic Agents/therapeutic use , Autistic Disorder/drug therapy , Clinical Trials as Topic , Clozapine/therapeutic use , Humans , Placebos , Risperidone/therapeutic useABSTRACT
O transtorno autista e o grupo de condições relacionadas definidas como transtornos invasivos do desenvolvimento são transtornos de neurodesenvolvimento crônicos que começam na infância precoce e afetam um número significativo de crianças e suas famílias. Ainda que as causas e muito da fisiopatologia do transtorno sejam desconhecidas, em anos recentes, vários tratamentos medicamentosos disponíveis têm sido identificados como contendo a promessa de aliviar alguns dos comportamentos mal-adaptativos mais comprometedores associados aos transtornos invasivos do desenvolvimento. No entanto, esses tratamentos não enfocam os sintomas nucleares da enfermidade e, geralmente, seus efeitos colaterais excedem os benefícios. Portanto, há uma necessidade substancial de novas medicações que sejam mais seguras e mais eficazes em tratar os sintomas comportamentais do autismo. O objetivo desta revisão é o de destacar as farmacoterapias correntes disponíveis e aquelas emergentes e que tenham potencial de melhorar as opções de tratamento de pacientes com transtornos invasivos do desenvolvimento.
